Sio Gene Therapies Ownership 2024 | Who Owns Sio Gene Therapies Now?
Institutional Ownership
0.09%
Insider Ownership
25.26%
Retail Ownership
74.66%
Institutional Holders
1.00
Sio Gene Therapies Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JBF CAPITAL, INC. | 3.57% | 0.24% | 2,639,127 | 2,209,527 | 514.32% | 1,068,846,000 | Mar 31, 2023 |
| CLADIS INVESTMENT ADVISORY, LLC | 0.11% | 0.03% | 80,000 | -70,000 | -46.67% | 32,320,000 | Mar 31, 2023 |
| MACQUARIE GROUP LTD | 0.09% | - | 64,170 | - | - | 26,000,000 | Mar 31, 2023 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.02% | 0.00% | 14,000 | 14,000 | 100.00% | 4,532,000 | Mar 31, 2023 |
| HUDSON BAY CAPITAL MANAGEMENT LP | - | - | - | -235,000 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -15,202 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -1,600 | -100.00% | - | Mar 31, 2023 |
| UBS GROUP AG | - | - | - | -80,100 | -100.00% | - | Mar 31, 2023 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -95,387 | -100.00% | - | Mar 31, 2023 |
| FRANKLIN RESOURCES INC | - | - | - | -55,570 | -100.00% | - | Mar 31, 2023 |
| RUBRIC CAPITAL MANAGEMENT LP | - | - | - | -7,000,000 | -100.00% | - | Mar 31, 2023 |
| TOWER VIEW INVESTMENT MANAGEMENT & RESEARCH LLC | - | - | - | -5,239 | -100.00% | - | Mar 31, 2023 |
| BOOTHBAY FUND MANAGEMENT, LLC | - | - | - | -30,000 | -100.00% | - | Mar 31, 2023 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -244 | -100.00% | - | Mar 31, 2023 |
| WELLS FARGO & COMPANY/MN | - | - | - | -2,373 | -100.00% | - | Mar 31, 2023 |
| WOLFF WIESE MAGANA LLC | - | - | - | -2,400 | -100.00% | - | Mar 31, 2023 |
| WESTERN STANDARD LLC | - | - | - | -294,397 | -100.00% | - | Mar 31, 2023 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -15,600 | -100.00% | - | Mar 31, 2023 |
| NORTHERN TRUST CORP | - | - | - | -87,153 | -100.00% | - | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | - | - | - | -902 | -100.00% | - | Mar 31, 2023 |
Sio Gene Therapies's largest institutional shareholder is JBF CAPITAL, INC., holding 3.57% of the company's total share outstanding, currently valued at $1.07B. The top 10 institutional shareholders own together 3.78% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JBF CAPITAL, INC. | 3.57% | 0.24% | 2,639,127 | 2,209,527 | 514.32% | 1,068,846,000 | Mar 31, 2023 |
| CLADIS INVESTMENT ADVISORY, LLC | 0.11% | 0.03% | 80,000 | -70,000 | -46.67% | 32,320,000 | Mar 31, 2023 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.02% | 0.00% | 14,000 | 14,000 | 100.00% | 4,532,000 | Mar 31, 2023 |
| MACQUARIE GROUP LTD | 0.09% | - | 64,170 | - | - | 26,000,000 | Mar 31, 2023 |
| HUDSON BAY CAPITAL MANAGEMENT LP | - | - | - | -235,000 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -15,202 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -1,600 | -100.00% | - | Mar 31, 2023 |
| UBS GROUP AG | - | - | - | -80,100 | -100.00% | - | Mar 31, 2023 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -95,387 | -100.00% | - | Mar 31, 2023 |
| FRANKLIN RESOURCES INC | - | - | - | -55,570 | -100.00% | - | Mar 31, 2023 |
| RUBRIC CAPITAL MANAGEMENT LP | - | - | - | -7,000,000 | -100.00% | - | Mar 31, 2023 |
| TOWER VIEW INVESTMENT MANAGEMENT & RESEARCH LLC | - | - | - | -5,239 | -100.00% | - | Mar 31, 2023 |
| BOOTHBAY FUND MANAGEMENT, LLC | - | - | - | -30,000 | -100.00% | - | Mar 31, 2023 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -244 | -100.00% | - | Mar 31, 2023 |
| WELLS FARGO & COMPANY/MN | - | - | - | -2,373 | -100.00% | - | Mar 31, 2023 |
| WOLFF WIESE MAGANA LLC | - | - | - | -2,400 | -100.00% | - | Mar 31, 2023 |
| WESTERN STANDARD LLC | - | - | - | -294,397 | -100.00% | - | Mar 31, 2023 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -15,600 | -100.00% | - | Mar 31, 2023 |
| NORTHERN TRUST CORP | - | - | - | -87,153 | -100.00% | - | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | - | - | - | -902 | -100.00% | - | Mar 31, 2023 |
The largest Sio Gene Therapies shareholder by % of total assets is JBF CAPITAL, INC.. The company owns 2.64M shares of Sio Gene Therapies (SIOX), representing 0.24% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JBF CAPITAL, INC. | 3.57% | 0.24% | 2,639,127 | 2,209,527 | 514.32% | 1,068,846,000 | Mar 31, 2023 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.02% | 0.00% | 14,000 | 14,000 | 100.00% | 4,532,000 | Mar 31, 2023 |
| MACQUARIE GROUP LTD | 0.09% | - | 64,170 | - | - | 26,000,000 | Mar 31, 2023 |
| FIFTH THIRD BANCORP | - | - | - | -125 | -100.00% | - | Mar 31, 2023 |
| PNC FINANCIAL SERVICES GROUP, INC. | - | - | - | -125 | -100.00% | - | Mar 31, 2023 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -244 | -100.00% | - | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | - | - | - | -902 | -100.00% | - | Mar 31, 2023 |
| CAPITAL ADVISORS, LTD. LLC | - | - | - | -1,305 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -1,600 | -100.00% | - | Mar 31, 2023 |
| WELLS FARGO & COMPANY/MN | - | - | - | -2,373 | -100.00% | - | Mar 31, 2023 |
| WOLFF WIESE MAGANA LLC | - | - | - | -2,400 | -100.00% | - | Mar 31, 2023 |
| TOWER VIEW INVESTMENT MANAGEMENT & RESEARCH LLC | - | - | - | -5,239 | -100.00% | - | Mar 31, 2023 |
| PRIMECAP MANAGEMENT CO/CA/ | - | - | - | -12,000 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -15,202 | -100.00% | - | Mar 31, 2023 |
| TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -15,453 | -100.00% | - | Mar 31, 2023 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -15,600 | -100.00% | - | Mar 31, 2023 |
| MERIT FINANCIAL GROUP, LLC | - | - | - | -15,750 | -100.00% | - | Mar 31, 2023 |
| BOOTHBAY FUND MANAGEMENT, LLC | - | - | - | -30,000 | -100.00% | - | Mar 31, 2023 |
| FRANKLIN RESOURCES INC | - | - | - | -55,570 | -100.00% | - | Mar 31, 2023 |
| CLADIS INVESTMENT ADVISORY, LLC | 0.11% | 0.03% | 80,000 | -70,000 | -46.67% | 32,320,000 | Mar 31, 2023 |
As of Mar 31 2023, Sio Gene Therapies's largest institutional buyer is JBF CAPITAL, INC.. The company purchased 2.21M stocks of SIOX, valued at $1.07B.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RUBRIC CAPITAL MANAGEMENT LP | - | - | - | -7,000,000 | -100.00% | - | Mar 31, 2023 |
| NEWTYN MANAGEMENT, LLC | - | - | - | -3,000,000 | -100.00% | - | Mar 31, 2023 |
| TANG CAPITAL MANAGEMENT LLC | - | - | - | -2,000,000 | -100.00% | - | Mar 31, 2023 |
| VANGUARD GROUP INC | - | - | - | -1,739,923 | -100.00% | - | Mar 31, 2023 |
| MORGAN STANLEY | - | - | - | -1,512,380 | -100.00% | - | Mar 31, 2023 |
| GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -432,270 | -100.00% | - | Mar 31, 2023 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -409,284 | -100.00% | - | Mar 31, 2023 |
| BLACKROCK INC. | - | - | - | -390,386 | -100.00% | - | Mar 31, 2023 |
| WESTERN STANDARD LLC | - | - | - | -294,397 | -100.00% | - | Mar 31, 2023 |
| CLEARLINE CAPITAL LP | - | - | - | -250,024 | -100.00% | - | Mar 31, 2023 |
| HUDSON BAY CAPITAL MANAGEMENT LP | - | - | - | -235,000 | -100.00% | - | Mar 31, 2023 |
| STATE STREET CORP | - | - | - | -173,621 | -100.00% | - | Mar 31, 2023 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -95,387 | -100.00% | - | Mar 31, 2023 |
| NORTHERN TRUST CORP | - | - | - | -87,153 | -100.00% | - | Mar 31, 2023 |
| UBS GROUP AG | - | - | - | -80,100 | -100.00% | - | Mar 31, 2023 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -70,925 | -100.00% | - | Mar 31, 2023 |
| CLADIS INVESTMENT ADVISORY, LLC | 0.11% | 0.03% | 80,000 | -70,000 | -46.67% | 32,320,000 | Mar 31, 2023 |
| FRANKLIN RESOURCES INC | - | - | - | -55,570 | -100.00% | - | Mar 31, 2023 |
| BOOTHBAY FUND MANAGEMENT, LLC | - | - | - | -30,000 | -100.00% | - | Mar 31, 2023 |
| MERIT FINANCIAL GROUP, LLC | - | - | - | -15,750 | -100.00% | - | Mar 31, 2023 |
As of Mar 31 2023, Sio Gene Therapies's biggest institutional seller is RUBRIC CAPITAL MANAGEMENT LP. The company sold -7.00M shares of SIOX, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BAADER BANK AKTIENGESELLSCHAFT | 0.02% | 0.00% | 14,000 | 14,000 | 100.00% | 4,532,000 | Mar 31, 2023 |
Sio Gene Therapies's largest new institutional shareholder by number of shares is BAADER BANK AKTIENGESELLSCHAFT, purchased 14.00K shares, valued at $4.53M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RUBRIC CAPITAL MANAGEMENT LP | - | - | - | -7,000,000 | -100.00% | - | Mar 31, 2023 |
| NEWTYN MANAGEMENT, LLC | - | - | - | -3,000,000 | -100.00% | - | Mar 31, 2023 |
| TANG CAPITAL MANAGEMENT LLC | - | - | - | -2,000,000 | -100.00% | - | Mar 31, 2023 |
| VANGUARD GROUP INC | - | - | - | -1,739,923 | -100.00% | - | Mar 31, 2023 |
| MORGAN STANLEY | - | - | - | -1,512,380 | -100.00% | - | Mar 31, 2023 |
| GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -432,270 | -100.00% | - | Mar 31, 2023 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -409,284 | -100.00% | - | Mar 31, 2023 |
| BLACKROCK INC. | - | - | - | -390,386 | -100.00% | - | Mar 31, 2023 |
| WESTERN STANDARD LLC | - | - | - | -294,397 | -100.00% | - | Mar 31, 2023 |
| CLEARLINE CAPITAL LP | - | - | - | -250,024 | -100.00% | - | Mar 31, 2023 |
| HUDSON BAY CAPITAL MANAGEMENT LP | - | - | - | -235,000 | -100.00% | - | Mar 31, 2023 |
| STATE STREET CORP | - | - | - | -173,621 | -100.00% | - | Mar 31, 2023 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | - | - | - | -95,387 | -100.00% | - | Mar 31, 2023 |
| NORTHERN TRUST CORP | - | - | - | -87,153 | -100.00% | - | Mar 31, 2023 |
| UBS GROUP AG | - | - | - | -80,100 | -100.00% | - | Mar 31, 2023 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -70,925 | -100.00% | - | Mar 31, 2023 |
| FRANKLIN RESOURCES INC | - | - | - | -55,570 | -100.00% | - | Mar 31, 2023 |
| BOOTHBAY FUND MANAGEMENT, LLC | - | - | - | -30,000 | -100.00% | - | Mar 31, 2023 |
| MERIT FINANCIAL GROUP, LLC | - | - | - | -15,750 | -100.00% | - | Mar 31, 2023 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -15,600 | -100.00% | - | Mar 31, 2023 |
| TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -15,453 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -15,202 | -100.00% | - | Mar 31, 2023 |
| PRIMECAP MANAGEMENT CO/CA/ | - | - | - | -12,000 | -100.00% | - | Mar 31, 2023 |
| TOWER VIEW INVESTMENT MANAGEMENT & RESEARCH LLC | - | - | - | -5,239 | -100.00% | - | Mar 31, 2023 |
| WOLFF WIESE MAGANA LLC | - | - | - | -2,400 | -100.00% | - | Mar 31, 2023 |
| WELLS FARGO & COMPANY/MN | - | - | - | -2,373 | -100.00% | - | Mar 31, 2023 |
| CITADEL ADVISORS LLC | - | - | - | -1,600 | -100.00% | - | Mar 31, 2023 |
| CAPITAL ADVISORS, LTD. LLC | - | - | - | -1,305 | -100.00% | - | Mar 31, 2023 |
| GROUP ONE TRADING, L.P. | - | - | - | -902 | -100.00% | - | Mar 31, 2023 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -244 | -100.00% | - | Mar 31, 2023 |
| PNC FINANCIAL SERVICES GROUP, INC. | - | - | - | -125 | -100.00% | - | Mar 31, 2023 |
| FIFTH THIRD BANCORP | - | - | - | -125 | -100.00% | - | Mar 31, 2023 |
Sio Gene Therapies's largest sold out institutional shareholder by shares sold is RUBRIC CAPITAL MANAGEMENT LP, sold -7.00M shares, valued at -, as of undefined.
Sio Gene Therapies Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| DELAWARE GROUP EQUITY FUNDS IV | 0.06% | 64,171 | - | - | Mar 28, 2024 |
| BRIDGEWAY FUNDS INC | 0.04% | 89,800 | - | - | Mar 28, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,718,988 | - | - | Mar 31, 2024 |
| GABELLI EQUITY TRUST INC | 0.00% | 2,596 | - | - | Dec 29, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 406,830 | - | - | Feb 29, 2024 |
| PRIMECAP Odyssey Funds | 0.00% | 11,800 | - | - | Jan 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 40,650 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 20,023 | - | - | Feb 29, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 279,138 | - | - | Jan 31, 2024 |
| VALIC Co I | 0.00% | 20,000 | - | - | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 20,749 | - | - | Jan 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 9,911 | - | - | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 123,826 | - | - | Mar 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 2,122 | - | - | Mar 31, 2024 |
| Legg Mason Global Asset Management Trust | 0.00% | 41,855 | - | - | Jan 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 200 | - | - | Mar 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 31 | - | - | Jan 31, 2024 |
Sio Gene Therapies's largest mutual fund holder by % of total assets is "DELAWARE GROUP EQUITY FUNDS IV", owning 64.17K shares, compromising 0.06% of its total assets.
Sio Gene Therapies Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 23 | 1 | -75.00% |
| 31 Mar, 23 | 4 | -88.57% |
| 31 Dec, 22 | 35 | 20.69% |
| 30 Sep, 22 | 29 | -3.33% |
| 30 Jun, 22 | 30 | -11.76% |
| 31 Mar, 22 | 34 | -32.00% |
| 31 Dec, 21 | 50 | -15.25% |
| 30 Sep, 21 | 59 | 18.00% |
| 30 Jun, 21 | 50 | -10.71% |
| 31 Mar, 21 | 56 | -13.85% |
| 31 Dec, 20 | 65 | - |
As of 30 Jun 23, 1 institutions are holding Sio Gene Therapies's shares, representing a decrease of -75.00% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 23 | 64,170 | -97.71% |
| 31 Mar, 23 | 2,797,297 | -84.95% |
| 31 Dec, 22 | 18,586,908 | -11.98% |
| 30 Sep, 22 | 21,117,126 | 2.12% |
| 30 Jun, 22 | 20,679,713 | 14.99% |
| 31 Mar, 22 | 17,983,396 | -21.93% |
| 31 Dec, 21 | 23,036,227 | 25.40% |
| 30 Sep, 21 | 18,370,779 | -10.91% |
| 30 Jun, 21 | 20,621,208 | 1.26% |
| 31 Mar, 21 | 20,365,114 | 43.91% |
| 31 Dec, 20 | 14,151,389 | - |
Sio Gene Therapies (SIOX) has 64.17K shares outstanding as of 30 Jun 23, down -97.71% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 23 | 0.09% | 0.61% |
| 31 Mar, 23 | 3.78% | 0.60% |
| 31 Dec, 22 | 25.13% | 3.08% |
| 30 Sep, 22 | 28.55% | 3.63% |
| 30 Jun, 22 | 28.03% | 4.71% |
| 31 Mar, 22 | 24.40% | 2.47% |
| 31 Dec, 21 | 31.41% | 4.95% |
| 30 Sep, 21 | 25.19% | 3.14% |
| 30 Jun, 21 | 28.30% | 2.97% |
| 31 Mar, 21 | 30.87% | 4.28% |
| 31 Dec, 20 | 26.86% | - |
As of 30 Jun 23, Sio Gene Therapies is held by 0.09% institutional shareholders, representing a 0.61% growth compared to 31 Mar 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 23 | - | -100.00% |
| 31 Mar, 23 | 2 | -85.71% |
| 31 Dec, 22 | 14 | 75.00% |
| 30 Sep, 22 | 8 | -33.33% |
| 30 Jun, 22 | 12 | 50.00% |
| 31 Mar, 22 | 8 | -61.90% |
| 31 Dec, 21 | 21 | -16.00% |
| 30 Sep, 21 | 25 | - |
| 30 Jun, 21 | 25 | -3.85% |
| 31 Mar, 21 | 26 | -50.00% |
| 31 Dec, 20 | 52 | - |
- institutional shareholders have increased their position in SIOX stock as of 30 Jun 23 compared to 2 in the previous quarter (a -100.00% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 23 | - | -100.00% |
| 31 Mar, 23 | 1 | -91.67% |
| 31 Dec, 22 | 12 | 33.33% |
| 30 Sep, 22 | 9 | -18.18% |
| 30 Jun, 22 | 11 | -31.25% |
| 31 Mar, 22 | 16 | - |
| 31 Dec, 21 | 16 | 33.33% |
| 30 Sep, 21 | 12 | - |
| 30 Jun, 21 | 12 | 9.09% |
| 31 Mar, 21 | 11 | - |
| 31 Dec, 20 | - | - |
- institutional shareholders have reduced their position in SIOX stock as of 30 Jun 23 compared to 1 in the previous quarter (a -100.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 23 | 1 | -75.00% | 64,170 | -97.71% | 0.09% | 0.61% | - | -100.00% | - | -100.00% |
| 31 Mar, 23 | 4 | -88.57% | 2,797,297 | -84.95% | 3.78% | 0.60% | 2 | -85.71% | 1 | -91.67% |
| 31 Dec, 22 | 35 | 20.69% | 18,586,908 | -11.98% | 25.13% | 3.08% | 14 | 75.00% | 12 | 33.33% |
| 30 Sep, 22 | 29 | -3.33% | 21,117,126 | 2.12% | 28.55% | 3.63% | 8 | -33.33% | 9 | -18.18% |
| 30 Jun, 22 | 30 | -11.76% | 20,679,713 | 14.99% | 28.03% | 4.71% | 12 | 50.00% | 11 | -31.25% |
| 31 Mar, 22 | 34 | -32.00% | 17,983,396 | -21.93% | 24.40% | 2.47% | 8 | -61.90% | 16 | - |
| 31 Dec, 21 | 50 | -15.25% | 23,036,227 | 25.40% | 31.41% | 4.95% | 21 | -16.00% | 16 | 33.33% |
| 30 Sep, 21 | 59 | 18.00% | 18,370,779 | -10.91% | 25.19% | 3.14% | 25 | - | 12 | - |
| 30 Jun, 21 | 50 | -10.71% | 20,621,208 | 1.26% | 28.30% | 2.97% | 25 | -3.85% | 12 | 9.09% |
| 31 Mar, 21 | 56 | -13.85% | 20,365,114 | 43.91% | 30.87% | 4.28% | 26 | -50.00% | 11 | - |
| 31 Dec, 20 | 65 | - | 14,151,389 | - | 26.86% | - | 52 | - | - | - |
Sio Gene Therapies Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Sio Gene Therapies's stock was made by Meswani Parag V on Feb 07 2022, selling - shares at - per share (valued at -).
Sio Gene Therapies Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2022 | 2 | 6 | 33.33% |
| Q4 2021 | 2 | 4 | 50.00% |
| Q2 2021 | 8 | - | - |
| Q1 2021 | 4 | 3 | 133.33% |
| Q4 2020 | 2 | - | - |
| Q3 2020 | 2 | - | - |
| Q2 2020 | 13 | 6 | 216.67% |
| Q1 2020 | 2 | - | - |
| Q3 2019 | 5 | 1 | 500.00% |
| Q2 2019 | 14 | - | - |
| Q1 2019 | 8 | - | - |
| Q4 2018 | 12 | - | - |
| Q3 2018 | 4 | 4 | 100.00% |
| Q2 2018 | 8 | - | - |
| Q1 2018 | 12 | 5 | 240.00% |
| Q4 2017 | 2 | 1 | 200.00% |
| Q3 2017 | 1 | - | - |
| Q2 2017 | 16 | 5 | 320.00% |
| Q4 2016 | - | - | - |
| Q3 2016 | - | - | - |
2 total buy trades, and 6 total sell trades (buy/sell ratio of 0.33%) were made by Sio Gene Therapies's insiders, as of Q1 2022.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2022 | - | - | - |
| Q4 2021 | - | - | - |
| Q2 2021 | - | - | - |
| Q1 2021 | 1 | - | - |
| Q4 2020 | 1 | - | - |
| Q3 2020 | 2 | - | - |
| Q2 2020 | - | - | - |
| Q1 2020 | 2 | - | - |
| Q3 2019 | - | - | - |
| Q2 2019 | 2 | - | - |
| Q1 2019 | 8 | - | - |
| Q4 2018 | 8 | - | - |
| Q3 2018 | 1 | - | - |
| Q2 2018 | 8 | - | - |
| Q1 2018 | 1 | - | - |
| Q4 2017 | - | - | - |
| Q3 2017 | - | - | - |
| Q2 2017 | 3 | - | - |
| Q4 2016 | - | - | - |
| Q3 2016 | - | - | - |
As of Q1 2022, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Sio Gene Therapies's stocks.
Sio Gene Therapies Peer Ownership
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| XOMA | XOMA Corporation |
| ALGS | Aligos Therapeutics, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| SRZN | Surrozen, Inc. |
| VCNX | Vaccinex, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| RZLT | Rezolute, Inc. |
| TPST | Tempest Therapeutics, Inc. |
| VINC | Vincerx Pharma, Inc. |
| TARA | Protara Therapeutics, Inc. |
| MOLN | Molecular Partners AG |
| NLTX | Neurogene Inc. |
| ABIO | ARCA biopharma, Inc. |
| TIL | Instil Bio, Inc. |
SIOX Ownership FAQ
Who Owns Sio Gene Therapies?
Sio Gene Therapies is owned by institutional shareholders (0.09%), insiders (25.26%), and public (74.66%). The largest institutional shareholder of Sio Gene Therapies is JBF CAPITAL, INC. (3.57% of total shares) and the top mutual fund owner is DELAWARE GROUP EQUITY FUNDS IV (0.06% of total shares).
Who are the major institutional shareholders of Sio Gene Therapies?
Sio Gene Therapies's major institutional shareholders are JBF CAPITAL, INC., CLADIS INVESTMENT ADVISORY, LLC, MACQUARIE GROUP LTD, BAADER BANK AKTIENGESELLSCHAFT, and HUDSON BAY CAPITAL MANAGEMENT LP. The top five shareholders own together 3.78% of the company's share outstanding.
How many Sio Gene Therapies shareholders are there?
As of Jun 2023, there are 1 institutional shareholders of Sio Gene Therapies.
What percentage of Sio Gene Therapies is owned by JBF CAPITAL, INC?
JBF CAPITAL, INC owns 2.64M shares of Sio Gene Therapies, representing 3.57% of the company's total shares outstanding, valued at $1.07B (as of Mar 2023).
What percentage of Sio Gene Therapies is owned by CLADIS INVESTMENT ADVISORY, LLC?
As of Mar 2023, CLADIS INVESTMENT ADVISORY, LLC holds 80K shares of Sio Gene Therapies (SIOX), compromising 0.11% of the company, valued at $32.32M.
What percentage of Sio Gene Therapies is owned by MACQUARIE GROUP LTD?
MACQUARIE GROUP LTD is the third largest holder of Sio Gene Therapies. The company owns 64.17K of the company's shares outstanding (worth $26M).